id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4976	Dattola, Annunziata; Bernardini , Nicoletta ; Campione , Elena ; Amore , Emanuele ; Amato , Simone ; Caldarola , Giacomo ; De Simone , Clara ; Giordano , Domenico; Moretta , Gaia ; Panasiti , Vincenzo ; Pagnanelli , Gianluca ; Roberti , Vincenzo ; Shumak, Ruslana Gaeta ; Skroza, Nevena; Tolino , Ersilia ; Tribuzi, Paola ; Zanframundo , Salvatore ; Bianchi , Luca ; Persechino , Severino ; Potenza , Concetta ; Pellacani , Giovanni ; Peris , Ketty ; Richetta , Antonio Giovanni 	Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy	2025	10	.pdf	application/pdf	5074	324	62	Over 36 weeks, bi- mekizumab significantly reduced mean PASI scores, from 16.6 ± 9.4 at baseline to 4.3 ± 5.2 at week 4 and 1.1 ± 1.7 at weeks 16 and 36 (P< 0.001). The percentage of patients achieving PASI 100 for the trunk increased from 52% at week 4 to 94% at weeks Figure 3.	cache/dpc-4976.pdf	txt/dpc-4976.txt